In this new article, our team at the University of Galway reviewed and analysed current research on the use of MSCs and MSC-EVs in treating corneal diseases.
Category: Results
New article: Are inactive ingredients in eye drops safe? A closer look at excipients safety, function an regulation.
Restore Vision has conducted the first comprehensive review of FDA-approved excipients in ophthalmic medications, examining their roles, safety, and the regulatory pathways required for approval for human use.
Antisense eye drops only or combined with fine needle diathermy could be used to regress corneal neovascularization in mice – study by UKK
At the recent ARVO meeting, Wei Zhang presented the latest findings from the University of Cologne on a new treatment to regress corneal neovascularization in mice
Genetic research shows promise for developing a treatment for the rare eye disease Aniridia – Study by UKK
At the recent ARVO meeting, Karina Hadriaan presented the latest findings from the University of Cologne on a new treatment to regress corneal neovascularization in mice
Effectiveness of a new eyedrop in healing wounds on the cornea in rats – Study by INSERM
At the recent ARVO meeting, Daniela Braz presented the latest findings from INSERM on the development of a new eye drop to treat cornea wounds in mice.
Exploring the use of spironolactone to treat diseases of the cornea – Study by INSERM
At the recent ARVO meeting, Raquel Gregorio presented the latest findings from INSERM on the use of spironolactone for treating corneal diseases.
A novel combination treatment offers promise for corneal vessel regression and longer graft survival – Study by UKK
At the recent ARVO meeting, Meert Mestanoglu presented UKK’s ongoing research on a novel combination treatment for corneal vessel regression.